Blog
Featured post
Truveta community expands to more than 40 healthcare and life science organizations
A leader in EHR data and analytics, Truveta welcomes new life science and healthcare partners
Ozempic, Wegovy, and Mounjaro: On- and off-label prescribing trends
Beginning in Fall 2022, the news media has reported extensively on the use of Glucagon-like peptide-1 receptor agonist (GLP-1s) for weight loss (Belluz, 2023). Physicians have...
A pragmatic suggestion for medical AI regulation
There is a growing global consensus that “we need to regulate AI”. The most commonly cited suggestion is that we create a new global government agency to issue licenses for...
Unlocking Insights: Stroke Research with Truveta
Every 40 seconds, someone in the United States has a stroke. Every 3 minutes and 14 seconds, someone dies from a stroke. The fifth leading cause of death in the US and a leading...
Truveta Spotlight: Dr. Marty Doerfler, EVP of Healthcare
Dr. Marty Doerfler has been an advocate for Truveta from its earliest days. He served as one of the original members of Truveta’s Board of Directors in his role at Northwell...
Q&A: Exploring with The Wall Street Journal Truveta’s EHR data on speech delays
The Wall Street Journal recently published a story, If Your Toddler Isn’t Talking Yet, the Pandemic Might Be to Blame, based on a new pre-print published by Truveta Research on...
Truveta expands its community to more than 40 healthcare and life science organizations
We are excited to announce the expansion of the Truveta community to include new life science partners, including Reprieve Cardiovascular and SK Life Science, joining previously...
Truveta collaboration with Harvard University researchers published in JAMA Network Open
Today Truveta announced a new research letter published in JAMA Network Open using de-identified patient data from Truveta Studio. Published in collaboration with Anupam B. Jena,...
Comparative effectiveness of SGLT2i vs. Metformin for first-line antidiabetic treatment
This blog is an extension of our poster presented at ISPOR, titled Real-World Effectiveness of SGLT2 Inhibitors Vs Metformin as First-Line Therapy in Type 2 Diabetes. ...
How better medical device data can create better patient outcomes
Medical device companies face a unique challenge when they want to study their product performance post-launch – a significant lack of detailed data on use of their device in...
